Document is current
Any future updates will be listed below
-
Authors
Agostinetto, Elisa https://orcid.org/0000-0003-0295-7511
de Azambuja, Evandro https://orcid.org/0000-0001-9501-4509
Lambertini, Matteo https://orcid.org/0000-0003-1797-5296
- License Information
-
More Information
Article History
Received: 3 November 2022
Accepted: 8 February 2023
First Online: 16 March 2023
Competing interests
: The authors declare no competing interests related to the present work. E.A. received consultancy fees/honoraria from Eli Lilly, Sandoz, AstraZeneca; research grant to her Institution from Gilead; support for attending medical conferences from Novartis, Roche, Eli Lilly, Genetic, Istituto Gentili, Daiichi Sankyo (all outside the submitted work). E.d.A. received honoraria and/or advisory board from Roche/GNE, Novartis, Seattle Genetics, Zodiac, Libbs and Pierre Fabre. Travel grants from Roche/GNE and GSK/Novartis. Research grant to his institution from Roche/GNE, Astra-Zeneca, GSK/Novartis and Servier (all outside the submitted work). M.L. received honoraria and/or advisory board from Roche, Novartis, Lilly, Pfizer, AstraZeneca, Daiichi Sankyo, Gilead, Seagen, MSD, Exact Sciences, Takeda, Ipsen, Sandoz, Libbs and Knight, a travel grant from Gilead and research support (to the Institution) from Gilead (all outside the submitted work).
